Ocugen, Inc. (NASDAQ:OCGN) is set to announce second quarter earning results on Friday 14th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, OCGN to report 2Q20 loss of $ 0.03 per share.
For the full year, analysts anticipate loss of $ 0.16 per share bottom line.
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of OCGN was $ 0.62, representing a 264.71 % increase from the 52 week low of $ 0.17 and a 96.44 % decrease over the 52 week high of $ 17.40.
The company has a market capital of $ 84.11 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”OCGN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases.
